Prot #CL1-95032-005: A Phase 1, Safety Lead-in and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas

Project: Research project

Project Details

StatusActive
Effective start/end date5/22/235/22/26

Funding

  • PPD Development (Prot #CL1-95032-005 // Prot #CL1-95032-005)
  • Servier Bio-Innovation LLC (Prot #CL1-95032-005 // Prot #CL1-95032-005)